Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Ticker
$VRDN
Sector
Primary listing
Employees
252
Headquarters
Website
VRDN Metrics
BasicAdvanced
$2.8B
-
-$3.32
1.01
-
Price and volume
Market cap
$2.8B
Beta
1.01
52-week high
$34.29
52-week low
$9.90
Average daily volume
1.4M
Financial strength
Current ratio
12.649
Quick ratio
12.372
Long term debt to equity
7.178
Total debt to equity
7.283
Interest coverage (TTM)
-73.44%
Profitability
EBITDA (TTM)
-362.935
Gross margin (TTM)
-378.38%
Net profit margin (TTM)
-483.57%
Operating margin (TTM)
-512.91%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-27.67%
Return on equity (TTM)
-49.16%
Valuation
Price to revenue (TTM)
32.785
Price to book
4.73
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
-8.389
Free cash flow yield (TTM)
-11.92%
Free cash flow per share (TTM)
-3.265
Growth
Revenue change (TTM)
23,359.93%
Earnings per share change (TTM)
8.21%
3-year revenue growth (CAGR)
241.95%
10-year revenue growth (CAGR)
30.35%
3-year earnings per share growth (CAGR)
7.01%
10-year earnings per share growth (CAGR)
-35.71%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Business Wire·1 month ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 months ago
Viridian Therapeutics Prepares for Transformational 2026
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $2.8B as of March 29, 2026.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of March 29, 2026.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of March 29, 2026.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.